Beta

    fda approve gedatolisib for advanced breast cancer

    Before Jul 1, 2027

    fda approve gedatolisib for advanced breast cancer. Best Yes near 84¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 84¢ · Best No: 23¢ · 1 platform

    • Kalshi: Yes 84¢ / No 23¢
    LIVE

    Before Jul 1, 2027

    Volume

    $87

    $0 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jul 1, 2027

    ~380 days left

    Category

    Culture

    84¢CHANCE OF YES79%21%
    Yes
    84¢
    Kalshi
    No
    23¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    84¢
    No
    23¢
    Vol
    $87
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2027, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 84¢: exit costs ~0.94¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jul 1, 2027
    Time Left380 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In